Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

883 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Safety, pharmacokinetic, and pharmacodynamic evaluations of PI-2301, a potent immunomodulator, in a first-in-human, single-ascending-dose study in healthy volunteers.
Kovalchin J, Krieger J, Collins K, Genova M, Augustyniak M, Masci A, Avril T, Gandon G, Patat A, Fauchoux N, Toutin C, Lacoste E, Patel U, Mascioli E, Zanelli E. Kovalchin J, et al. Among authors: patel u. J Clin Pharmacol. 2011 May;51(5):649-60. doi: 10.1177/0091270010373930. Epub 2010 Oct 12. J Clin Pharmacol. 2011. PMID: 20940336 Clinical Trial.
Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response.
Kovalchin J, Krieger J, Genova M, Collins K, Augustyniak M, Masci A, Hittinger T, Kuca B, Edan G, Braudeau C, Rimbert M, Patel U, Mascioli E, Zanelli E. Kovalchin J, et al. Among authors: patel u. J Neuroimmunol. 2010 Aug 25;225(1-2):153-63. doi: 10.1016/j.jneuroim.2010.04.008. Epub 2010 May 13. J Neuroimmunol. 2010. PMID: 20466440 Clinical Trial.
883 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page